What is the appropriate management for a patient with facial pain radiating to the right ear, gingival inflammation, and a history of migraine, including the use of ketorolac, methylprednisolone, and promethazine?

Management of Facial Pain with Gingival Inflammation and Migraine History

Immediate Diagnostic Priorities

Before initiating the proposed treatment regimen, you must first systematically rule out life-threatening causes and establish whether this represents migraine, dental pathology, or another etiology.

Critical Red Flag Assessment

• If the patient is over 50 years old, giant cell arteritis must be excluded immediately by checking ESR and CRP within hours, as this is a medical emergency that can cause irreversible vision loss if missed 1.
• Look specifically for jaw claudication, temporal artery tenderness or absent pulse, visual disturbances, scalp tenderness, fever, malaise, or weight loss—all indicators of giant cell arteritis 1, 2.

Establish the Primary Diagnosis

The presence of gingival inflammation strongly suggests a dental or periodontal cause rather than primary migraine, which should fundamentally alter your treatment approach:

• Dental disease is the most common acute cause of facial pain and should be evaluated by a dentist if pain is triggered by thermal changes or eating 1.
• Migraine with isolated facial pain requires attacks lasting 4–72 hours with at least two of the following: unilateral location, throbbing/pulsatile quality, moderate-to-severe intensity, worsening with routine activity, plus nausea/vomiting OR photophobia/phonophobia 3.
• The combination of gingival inflammation with facial pain radiating to the ear suggests odontogenic infection or periodontal abscess rather than migraine 1.

Key Distinguishing Features to Document

• Pain duration and pattern: Migraine attacks last 4–72 hours and are episodic, not continuous 3.
• Pain quality: Migraine is throbbing/pulsatile, while dental pain is often sharp or aching and worsens with chewing 3, 1.
• Triggers: Migraine has typical triggers (hormonal changes, certain foods, sensory stimuli, missed meals, stress), while dental pain worsens with thermal changes, eating, or percussion 3, 1.
• Associated symptoms: Migraine includes nausea, photophobia, phonophobia; dental infection may include fever, facial swelling, trismus 3, 1.

---

Evaluation of the Proposed Treatment Regimen

Ketorolac Assessment

Ketorolac IV should be offered (level B recommendation) for acute migraine in the emergency setting 4:

• Ketorolac is likely effective based on class I evidence and is specifically recommended by the 2025 American Headache Society guideline for parenteral migraine treatment 4.
• Ketorolac is FDA-approved only for short-term (≤5 days) management of moderately severe acute pain requiring opioid-level analgesia, usually in postoperative settings 5.
• Ketorolac demonstrated similar efficacy to phenothiazines and metoclopramide for migraine pain relief at 1 hour, and may offer better pain control than sumatriptan and dexamethasone 6.
• Critical limitation: Ketorolac is appropriate for acute migraine treatment but does not address the gingival inflammation, which requires dental evaluation and possible antibiotics 1, 5.

Promethazine Assessment

Promethazine is NOT recommended as monotherapy for acute migraine and carries significant safety concerns:

• When combined with meperidine, promethazine showed no superiority over ketorolac alone for migraine treatment (68% vs 55% response rates, not statistically significant) 7.
• Promethazine IV carries serious risks: intra-arterial injection can cause tissue necrosis and gangrene; perivascular extravasation causes severe tissue injury; contains sodium metabisulfite which may cause anaphylactic reactions in susceptible individuals 8.
• If intra-arterial injection occurs, there is no proven successful management, and the injection must be stopped immediately if the patient complains of pain during administration 8.
• Promethazine may lower seizure threshold, cause bone marrow depression, and precipitate neuroleptic malignant syndrome 8.
• The 2025 AHS guideline does not recommend promethazine for acute migraine treatment in the emergency setting 4.

Methylprednisolone Assessment

Methylprednisolone is not indicated for acute migraine pain relief but may reduce headache recurrence:

• Corticosteroids (including dexamethasone) are useful in reducing headache recurrence within 24–72 hours after discharge from the emergency department, where recurrence rates can exceed 50% 9.
• Dexamethasone IV may be offered (level C recommendation) for migraine in the emergency setting, but methylprednisolone is not specifically studied or recommended 4.
• One small case series suggested IV methylprednisolone may benefit post-infectious new daily persistent headache, but this is not applicable to acute migraine with gingival inflammation 10.
• Steroids do not provide acute pain relief—they function as adjunctive therapy to prevent recurrence, not as primary treatment 9.

---

Recommended Management Algorithm

Step 1: Address the Gingival Inflammation First

The presence of gingival inflammation with facial pain radiating to the ear requires immediate dental evaluation:

• Refer to dentist or oral surgeon urgently (within 24 hours) for evaluation of periodontal abscess, dental infection, or other odontogenic pathology 1.
• Consider empiric antibiotics if signs of infection (fever, facial swelling, trismus) while awaiting dental evaluation 1.

Step 2: Acute Pain Management

For acute pain relief in the emergency setting, prioritize evidence-based migraine treatments:

• First-line: Prochlorperazine IV (10 mg) must be offered (level A recommendation) as it is highly likely to be effective based on multiple class I studies and is superior or equivalent to all other treatments 4, 9.
• Alternative: Metoclopramide IV (10 mg) should be offered (level B recommendation) as it is likely effective and, when combined with diphenhydramine, is superior to triptans and NSAIDs 4, 9.
• Ketorolac IV (30 mg) should be offered (level B recommendation) as adjunctive therapy or if dopamine antagonists are contraindicated 4.
• Avoid promethazine due to lack of evidence for efficacy as monotherapy and significant safety concerns with IV administration 8, 7, 4.

Step 3: Adjunctive Therapy to Prevent Recurrence

• Dexamethasone IV (10–24 mg) may be offered (level C recommendation) to reduce headache recurrence after discharge, but only after acute pain is controlled 4, 9.
• Methylprednisolone is not specifically recommended; use dexamethasone instead if corticosteroid therapy is desired 4.

Step 4: Disposition and Follow-up

• Ensure dental follow-up within 24–48 hours for evaluation and treatment of gingival inflammation 1.
• If migraine features are confirmed, consider neurology referral for preventive therapy if attacks occur ≥4 days per month 3.
• Educate patient on migraine triggers and provide rescue medication (oral triptan or NSAID) for future attacks 3.

---

Critical Pitfalls to Avoid

• Do not treat facial pain as migraine without excluding dental pathology, especially when gingival inflammation is present—this is the most common cause of acute facial pain 1.
• Do not use promethazine IV without extreme caution due to risk of intra-arterial injection, tissue necrosis, and lack of efficacy data as monotherapy 8, 7.
• Do not rely on steroids for acute pain relief—they prevent recurrence but do not provide immediate analgesia 9, 4.
• Do not use opioids (meperidine, hydromorphone) for migraine—they are inferior to dopamine antagonists and hydromorphone must not be offered (level A recommendation) 4, 9.
• Do not exceed 5 days total duration of ketorolac (IV plus oral combined) due to increased risk of adverse effects 5.